|
Peptide vaccine for the treatment of type 1 diabetes, acts to protect the insulin producing beta-cells from auto immune destruction. DiaPep277® is licensed to Andromeda (a subsidiary of Clal Biotechnological Industries) and has successfully completed phase II clinical development. A pivotal phase III trial for the treatment of type 1 diabetes commenced in September 2005.
|
|
Combination of two fully human monoclonal antibodies against the hepatitis B virus surface antigen, HBsAg. It is being developed to prevent hepatitis B, known as HBV, re-infection following liver transplantation. Summary of the Phase IIb trial in liver transplant patients is available. Yeda is currently seeking potential collaboration.
|
|
Disrupts the acto-cytoskeleton of the trabecular meshwork in the eye, reduces intraocular pressure and thus serves as a potential treatment for glaucoma. Developed and owned jointly with University of Wisconsin and its TTO (WARF) & licensed to Inspire Pharmaceuticals Inc. Currently in phase I clinical trials to evaluate the safety and tolerability in subjects with bilateral ocular hypertension or early primary open angle glaucoma.
|
|
(recombinant IFNα, LEX System), a recombinant IFNα produced in Biolex’s proprietary LEX System(SM) which is under license from Yeda, combined with Biolex’ advanced controlled-release drug delivery technology. Currently in phase IIa clinical trials for HCV.
Read more >>
|
|
Novel angiogenesis inhibitor drug, characterized by its unique target specificity, lack of toxicity and by its oral bioavailability. Currently in phase II clinical trials for lung cancer. Licensed to ORA BIO Ltd.
|
|